Follows people with blood cancers treated with tisagenlecleucel in Brazil
Observes Brazilian patients with lymphoma or leukemia receiving tisagenlecleucel, a cell therapy.
Plain-language title generated from the registry record
Registry title: Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Key facts
- Where
- Curitiba, Minas Gerais, Salvador, and São Paulo, BrazilSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 100 years old?
Source: NCT05541341, who can take part
Where in Brazil
- CuritibaCuritiba, BrazilTaking people
- Minas GeraisMinas Gerais, BrazilTaking people
- SalvadorSalvador, BrazilTaking people
- São PauloSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT05541341
- Record updated
- 10 November 2026
- Original description
This will be a multicenter, national, non-interventional, prospective cohort studyRead full original descriptionShow less
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies: a 15-year Prospective Registry Study on Three Cohorts.
This will be a multicenter, national, non-interventional, prospective cohort study
Inclusion: Patients eligible for inclusion in this study must meet the following criteria:; Patients who receive tisagenlecleucel infusion in the commercial setting or out-of-specification (OOS) use, AND; Signed informed consent must be obtained prior to participation in study, AND; For ALL participants:; Patients of any gender aged 0-17 years (named as pediatric) with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR; Patients of any gender, aged 18-25 years (named as adults) - with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR; For DBLCL and FL participants:; Patients of any gender aged 18 years or older, who have been diagnosed with relapsed/ refractory Diffuse Large B-cell Lymphoma and received tisagenlecleucel infusion.
Exclusion: Patients who received tisagenlecleucel infusion as part of any interventional clinical trial; Patients who did not consent to data collection.